Welcome to our dedicated page for Processa Pharmaceuticals Common news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals Common stock.
Processa Pharmaceuticals, Inc. (symbol: PCSA) is a clinical-stage biopharmaceutical company, founded in October 2017 and headquartered in Hanover, Maryland. The company's mission is to develop products that can significantly improve the survival and quality of life for patients with high unmet medical needs, particularly in the field of oncology.
Processa Pharmaceuticals specializes in the development of Next Generation Chemotherapy (NGC) oncology drug products using a unique 'regulatory science' approach. The company's primary focus is to advance its pipeline of proprietary small molecule oncology drugs. These NGC products are new chemical entities designed to alter the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites, while preserving the original mechanisms of action that kill cancer cells.
The company's current pipeline includes three promising NGC treatments:
- NGC-Capecitabine (NGC-Cap): This therapy involves Capecitabine administered with PCS6422, aiming to enhance efficacy and reduce side effects.
- PCS3117 (NGC-Gemcitabine or NGC-Gem): A novel formulation intended to improve the therapeutic profile of Gemcitabine.
- PCS11T (NGC-Irinotecan or NGC-Iri): Another innovative treatment designed to optimize the benefits of Irinotecan.
Processa Pharmaceuticals is committed to leveraging its expertise in regulatory science to bring these next-generation treatments to market. The company's strategic partnerships and ongoing clinical trials play a crucial role in advancing its mission and providing hope to patients battling cancer. For the latest updates and more information, investors can contact Patrick Lin at plin@processapharma.com.
Processa Pharmaceuticals (NASDAQ: PCSA) announced it will join the Russell Microcap Index after the annual reconstitution on June 28, 2021. This inclusion signifies a substantial milestone for the company, potentially enhancing its visibility among investors and providing access to a wider investment base. The Russell indexes are crucial as they benchmark approximately $10.6 trillion in assets, suggesting that Processa's membership could attract more institutional investors. The company focuses on developing therapies for unmet medical needs, emphasizing treatments for various serious conditions.
Processa Pharmaceuticals (NASDAQ: PCSA) announced its participation in the LD Micro Virtual Investor Conference, scheduled for June 9, 2021, at 1:30 p.m. ET, Track 4. Management will present details about the company's pipeline aimed at improving survival and quality of life for patients with unmet medical needs. Current programs include PCS6422 for cancer treatments, PCS499 for ulcerative necrobiosis lipoidica, and PCS12852 for gastrointestinal issues. A live audio webcast of the event will be available for attendees.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two upcoming investor conferences. They will attend the Craig-Hallum Virtual Institutional Investor Conference on June 2, focusing on one-on-one meetings. Additionally, they will present at the Jefferies Virtual Healthcare Conference on June 4, from 2:00 to 2:25 PM EST, where one-on-one meetings will also be available. The company is committed to developing products to enhance survival and quality of life for patients with unmet medical needs.
Processa Pharmaceuticals (NASDAQ: PCSA) has dosed its first patient in a Phase 2B trial for PCS499, targeting ulcerations in patients with Necrobiosis Lipoidica (NL), a rare skin disease affecting collagen. The trial aims to assess the efficacy of PCS499 compared to a placebo. Approximately 30% of NL patients experience open ulcers that impair quality of life. Sian Bigora, Chief Development Officer, expressed optimism about the trial's potential impact on treatment options for this underserved condition.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two investor conferences aimed at addressing unmet medical needs. The events include the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021 (on-demand presentations) and The Benchmark Company Healthcare House Call Virtual Conference on May 26, 2021 (one-on-one meetings). Processa focuses on developing treatments for conditions such as metastatic colorectal cancer, breast cancer, and GI motility disorders. The company aims to enhance patient survival and quality of life through existing clinical evidence.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) reported financial results for the first quarter ended March 31, 2021, showcasing significant advancements in its clinical drug pipeline. The company has commenced trials for its product candidates PCS6422 and PCS499, targeting markets exceeding $1 billion each. As of March 31, 2021, cash and equivalents reached $23 million, compared to $15.4 million at year-end 2020. The company reported a net loss of $2.1 million for the quarter. Upcoming milestones include the submission of an IND application for PCS12852 and interim trial results for PCS6422 by late 2021.
Processa Pharmaceuticals (NASDAQ: PCSA) will host a conference call on May 13, 2021, at 5:30 PM EST to discuss its Q1 2021 results and provide updates on its clinical pipeline. The call can be accessed via a toll-free number or an international line. The company focuses on developing products to improve survival and quality of life for patients with unmet medical needs, with active pipeline programs for conditions like metastatic colorectal cancer, breast cancer, and GI motility disorders.
Processa Pharmaceuticals reported significant progress in 2020, including the in-licensing of three programs with potential markets exceeding $1 billion each. The company anticipates dosing the first patients for PCS6422 and PCS499 in Q2 2021. Financial results show a net loss of $14.4 million, compared to $3.4 million in 2019. Processa's cash and equivalents stood at $15.4 million at year-end 2020, bolstered by recent fundraising totaling $27.3 million. Key upcoming milestones include FDA submissions and interim results for the ongoing clinical trials.
Processa Pharmaceuticals (NASDAQ: PCSA) will host a conference call on March 25, 2021, at 5:30 p.m. ET to discuss its fourth quarter 2020 results and clinical pipeline updates. Investors can join the call via a toll-free number or through a live webcast. Processa focuses on developing products for patients with unmet medical needs, with programs targeting cancers and gastrointestinal disorders. The company highlights its experienced development team, which has been involved with over 30 FDA drug approvals.
Processa Pharmaceuticals has selected 5 U.S. clinical sites for its Phase 2B trial of PCS499, aimed at treating ulcerative necrobiosis lipoidica. The trial, led by Dr. Misha Rosenbach, will evaluate the efficacy and safety of PCS499, with patient recruitment expected to start within 30-60 days. The condition affects the skin and can cause painful ulcerations, with no effective treatments currently available. Preliminary evaluations suggest PCS499 may close ulcers within months, which could significantly improve patient outcomes.
FAQ
What is the current stock price of Processa Pharmaceuticals Common (PCSA)?
What is the market cap of Processa Pharmaceuticals Common (PCSA)?
What is Processa Pharmaceuticals, Inc.?
When was Processa Pharmaceuticals founded?
Where is Processa Pharmaceuticals headquartered?
What is the mission of Processa Pharmaceuticals?
What does NGC stand for?
What are the main products in Processa Pharmaceuticals' pipeline?
What is the unique approach of Processa Pharmaceuticals?
How can investors get more information about Processa Pharmaceuticals?
What recent achievements has Processa Pharmaceuticals made?
Does Processa Pharmaceuticals have any partnerships?
